Egetis Therapeutics Q3’22: Our Comment - Redeye
Bildkälla: Stockfoto

Egetis Therapeutics Q3’22: Our Comment - Redeye

Redeye comments on Egetis’ Q3 report and reiterate our view (for now) of the company.

Börsvärldens nyhetsbrev